Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Chen S.-C.Huang Y.-H.Chen M.-H.Hung Y.-P.Lee R.-C.YU-YUN SHAOChao Y.2022-10-252022-10-2520221471-2407https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122956162&doi=10.1186%2fs12885-022-09173-4&partnerID=40&md5=8b8ec554a2d33d1f72e4cad989a81437https://scholars.lib.ntu.edu.tw/handle/123456789/623990Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching studyjournal article10.1186/s12885-022-09173-4350166372-s2.0-85122956162